174 related articles for article (PubMed ID: 35910024)
1. Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q; Peng J; Xu Z; Liang Q; Cai Y; Peng B; He Q; Yan Y
Front Bioeng Biotechnol; 2022; 10():806851. PubMed ID: 35910024
[TBL] [Abstract][Full Text] [Related]
2. A pan-cancer analysis of the role of
Ding G; Ma T; Zhang K; Chen G; Shen J; Zhang S; Li K; Zhao C; Wang F; Sun J; Wang J
Biotechnol Genet Eng Rev; 2023 Mar; ():1-16. PubMed ID: 36971139
[TBL] [Abstract][Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of zinc and ring finger 3 in prognostic value and pan-cancer immunity.
Liu M; Zhao H; Peng S; Wu Y; Liu Y; Sun W; Zen K; Sun X
FASEB J; 2024 Mar; 38(5):e23523. PubMed ID: 38457275
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
6. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
8. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H; Zhang B; Sun Z
Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
Fei L; Lu Z; Xu Y; Hou G
Front Genet; 2022; 13():920897. PubMed ID: 36035140
[No Abstract] [Full Text] [Related]
11. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
12. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
[TBL] [Abstract][Full Text] [Related]
13. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
Li L; Feng Q; Wang X
Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
[TBL] [Abstract][Full Text] [Related]
14. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J; Hu K; Zhou L; Huang J; Zeng S; Xu Z; Yan Y
Front Oncol; 2020; 10():560615. PubMed ID: 33178590
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the novel omicron receptor AXL in cancers.
Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
[TBL] [Abstract][Full Text] [Related]
17. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
18. Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
Zhou Z; Peng B; Li J; Gao K; Cai Y; Xu Z; Yan Y
Sci Rep; 2021 Sep; 11(1):18366. PubMed ID: 34526571
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
20. Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer.
Liang T; Han L; Guo L
Comput Struct Biotechnol J; 2020; 18():1238-1248. PubMed ID: 32542110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
